SCHEMBL679101

SCHEMBL679101

Cc1cc(C)c(C(C)(OP(O)O)c2c(C)cc(C)cc2C(C)(C)C)c(C(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CA2 P00918 1/20 0.42
POLB P06746 1/20 0.42
TYR P14679 1/20 0.42
HSPA5 P11021 1/20 0.36
CYP2C9 P11712 3/20 0.35
CYP2C19 P33261 3/20 0.35
HIF1A Q16665 2/20 0.35
CYP2D6 P10635 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL39017 0.86 POLB (0.34) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL2264844 0.86 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL5455454 0.85 POLB (0.33) POLBCYP2C9CYP2C19CYP1A2
SCHEMBL27974118 0.75 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL8919537 0.74
SCHEMBL4201014 0.72 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL29398621 0.72 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL77703 0.71 POLB (0.36) POLB
SCHEMBL1664850 0.68 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1CA2POLBTYR
SCHEMBL373554 0.68 SMN1; SMN2 (0.35) SMN1; SMN2ALDH1A1CA2POLBTYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4306567-B1 CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ADHESIVE ADEKA CORP (JP) 2025-06-04 EP disclosed
US-20240317967-A1 CURABLE RESIN COMPOSITION ADEKA CORPORATION (JP) 2024-09-26 US disclosed
US-20240141094-A1 CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ADHESIVE ADEKA CORPORATION (JP) 2024-05-02 US disclosed
US-20240084065-A1 NOVEL COMPOUND, AND CURABLE RESIN COMPOSITION CONTAINING SAID COMPOUND ADEKA CORPORATION (JP) 2024-03-14 US disclosed
EP-4306567-A1 CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ADHESIVE ADEKA CORPORATION (JP) 2024-01-17 EP disclosed
EP-4289883-A1 CURABLE RESIN COMPOSITION ADEKA CORPORATION (JP) 2023-12-13 EP disclosed
EP-2848646-B1 CELLULOSE RESIN COMPOSITION ADEKA CORP (JP) 2023-11-08 EP disclosed
US-10578774-B2 Retardation-increasing agent, cellulose-based resin composition using same, and film ADEKA CORPORATION (JP) 2020-03-03 US disclosed
EP-2868694-B1 CELLULOSE ESTER-BASED RESIN COMPOSITION ADEKA CORP (JP) 2019-09-25 EP disclosed
US-20190048135-A1 MODIFIER FOR RESIN, RESIN COMPOSITION, AND FILM IN WHICH SAME IS USED ADEKA CORPORATION (JP) 2019-02-14 US disclosed
US-20110319537-A1 VINYL CHLORIDE RESIN COMPOSITION ADEKA CORPORATION (JP) 2011-12-29 US disclosed
US-20110288218-A1 VINYL CHLORIDE RESIN COMPOSITION ADEKA CORPORATION (JP) 2011-11-24 US disclosed
US-20110277664-A1 CELLULOSE RESIN COMPOSITION AND CELLULOSE RESIN FILM ADEKA CORPORATION (JP) 2011-11-17 US disclosed
US-20110197784-A1 CELLULOSE RESIN COMPOSITION AND CELLULOSE RESIN FILM ADEKA CORPORATION (JP) 2011-08-18 US disclosed
US-20110015322-A1 CELLULOSE RESIN COMPOSITION AND CELLULOSE RESIN FILM ADEKA CORPORATION (JP) 2011-01-20 US disclosed
US-20110003917-A1 POLYLACTIC ACID RESIN COMPOSITION ADEKA CORPORATION (JP) 2011-01-06 US disclosed
EP-2253667-A1 POLYLACTIC ACID RESIN COMPOSITION Adeka Corporation (JP) 2010-11-24 EP disclosed
EP-2045291-A1 VINYL CHLORIDE RESIN COMPOSITION Adeka Corporation (JP) 2009-04-08 EP disclosed
US-20030162870-A1 Flame-retardant resin composition ASAHI DENKA CO., LTD. (JP) 2003-08-28 US disclosed
EP-1304350-A1 Flame-retardant resin composition Asahi Denka Co., Ltd. (JP) 2003-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240084065-A1 NOVEL COMPOUND, AND CURABLE RESIN COMPOSITION CONTAINING SAID COMPOUND PSMC6, CAND1, RBX1 SMN1; SMN2 508/4885ALDH1A1 709/4885CA2 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.